Novo Nordisks semaglutide, the GLP-1 analog used in Ozempic and Wegovy, showed an average weight loss of 10.6% at 68 weeks with the 2.4 mg dose in adults with type 2 diabetes and obesity or overweight in the STEP 2 Phase 3 trial
Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy
Step 7: Initiate Therapy with Structured Monitoring Begin GLP-1 therapy with a clear, structured plan for monitoring progress and adjusting treatment as needed
Ive had one patient develop severe panic attacks that resolved when we discontinued the medication
Additionally, there is evidence that, in contrast to a matched group of family members without TP53 mutations, cancer-free LFS patients present clinical indicators of elevated oxidative stress and autoimmunity
Primary Target Tissue MOTS-c: The entire metabolic system, with a heavy emphasis on skeletal muscle tissue and systemic insulin regulation
